As glucagon-like peptide 1 (GLP-1) receptor agonists gain recognition for their efficacy in other inflammatory skin conditions, such as psoriasis and hidradenitis suppurativa, this case supports further exploration of their role in managing FD and other refractory dermatologic diseases. The gene discussed is GCG; the disease is psoriasis.